Sage shares get a bump from a snapshot of new PhII depression data
Sage Therapeutics $SAGE has had a lot of success posting interim snapshots on the data it’s been gathering for its pipeline drugs. And the biotech scored another surge in its share price today with a sliver of data from the first stage of its Phase II study of its depression drug SAGE-217.
Looking at 13 patients – a tiny group for a disease like depression – investigators say that 11 of them demonstrated a minimum 50% reduction in disease scores. And 8 of them achieved remission.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.